[{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"e91a001c-1388-4b9d-9fd5-c4bd92315a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579523","created_at":"2021-01-18T21:51:25.345Z","updated_at":"2025-02-25T15:18:52.701Z","phase":"Phase 1","brief_title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","source_id_and_acronym":"NCT04579523","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"d888b6c9-4b44-4498-aef7-22dac96f744f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163357","created_at":"2021-01-18T04:38:10.114Z","updated_at":"2024-07-02T16:35:00.426Z","phase":"Phase 1","brief_title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","source_id_and_acronym":"NCT01163357","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/28/2011","start_date":" 01/28/2011","primary_txt":" Primary completion: 07/20/2019","primary_completion_date":" 07/20/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"},{"id":"c2516a83-e25b-4521-afde-eaaf91d0d42c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03441958","created_at":"2021-01-18T16:58:32.149Z","updated_at":"2024-07-02T16:35:20.229Z","phase":"Phase 1/2","brief_title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","source_id_and_acronym":"NCT03441958","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" CD34","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/07/2018","start_date":" 03/07/2018","primary_txt":" Primary completion: 10/28/2023","primary_completion_date":" 10/28/2023","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2024-02-08"},{"id":"bf4d31e7-3a74-43c0-9ba3-0d9c7fa6780e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03531736","created_at":"2021-01-18T17:23:50.599Z","updated_at":"2024-07-02T16:35:27.515Z","phase":"Phase 1","brief_title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","source_id_and_acronym":"NCT03531736","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-30"},{"id":"79b87011-f88c-4a4b-b57c-fa97cf0c37d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02308280","created_at":"2022-01-21T21:58:53.578Z","updated_at":"2024-07-02T16:35:32.703Z","phase":"Phase 2","brief_title":"Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients","source_id_and_acronym":"NCT02308280","lead_sponsor":"Maisonneuve-Rosemont Hospital","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 09/27/2018","primary_completion_date":" 09/27/2018","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2023-10-19"},{"id":"55f48584-0a3e-41d6-a7ea-babf85b2ff5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03342144","created_at":"2021-01-18T16:30:28.943Z","updated_at":"2024-07-02T16:35:36.565Z","phase":"","brief_title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","source_id_and_acronym":"NCT03342144","lead_sponsor":"AbbVie","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/04/2017","start_date":" 12/04/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-21"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"895fbde3-58eb-4bbb-b7c0-359c9d1de505","acronym":"","url":"https://clinicaltrials.gov/study/NCT02504359","created_at":"2021-01-18T12:05:19.799Z","updated_at":"2024-07-02T16:36:38.273Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma","source_id_and_acronym":"NCT02504359","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • methotrexate • Ninlaro (ixazomib) • carmustine • melphalan • Starasid (cytarabine ocfosfate) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 07/20/2015","start_date":" 07/20/2015","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 09/09/2020","study_completion_date":" 09/09/2020","last_update_posted":"2020-11-23"},{"id":"03b35f16-d501-472b-8e72-f8828b4fc9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04011293","created_at":"2021-01-18T19:42:25.117Z","updated_at":"2024-07-02T16:36:58.292Z","phase":"Phase 1","brief_title":"A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04011293","lead_sponsor":"Shandong University","biomarkers":" TP53 • CD19","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative","tags":["TP53 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • CD19 positive • CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yorwida (inaticabtagene autoleucel)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-07-08"}]